Immpact Bio Is A Clinical Stage Biotechnology Company Focused On Developing Chimeric Antigen Receptorcart Cell Therapiesfounded In 2017 In Israelthe Company Aims To Tackle Significant Challenges In Treating Cancer And Autoimmune Diseasesits Innovative Technologies Are Designed To Accurately Identify And Eliminate Cancerous And Diseased Cells While Preserving Healthy Tissues In 2021Immpact Bio Merged With Kalthera And Established Its Corporate Offices In West Hillscaliforniaalong With A Clinical Manufacturing Facilityas Of October 2024The Company Was Acquired By Lyell Immunopharmaenhancing Lyell S Pipeline Of Next Generation Car T Cell Therapiesimmpact Bio Is Recognized For Its Commitment To Improving Patient Outcomes And Has Been Listed As One Of The Best Places To Work In The Biotech Industry
